ResearcherVeterans Health AdministrationNo recent work listed

Jack L. Arbiser

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6798-6383; OpenAlex author ID A5004887935. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper

Papers 1

Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Last author DOI 10.18632/oncotarget.10514 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Katherine T. Ostapoff · 1 shared paper, 2016 · strength 0.06
- Paper Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. DOI 10.18632/oncotarget.10514 ↗
Volkan N. Adsay · 1 shared paper, 2016 · strength 0.06
- Paper Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. DOI 10.18632/oncotarget.10514 ↗
Begoña Díaz · 1 shared paper, 2016 · strength 0.06
- Paper Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. DOI 10.18632/oncotarget.10514 ↗
Rolf A. Brekken · 1 shared paper, 2016 · strength 0.06
- Paper Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. DOI 10.18632/oncotarget.10514 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.